Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura
- 27 February 2007
- journal article
- case report
- Published by Wiley in European Journal of Haematology
- Vol. 78 (5) , 449-452
Abstract
A case of relapsing and refractory thrombotic thrombocytopenic purpura received mycophenolate mofetil (MMF) to attempt to maintain remission. The possible use of MMF in thrombotic thrombocytopenic purpura is discussed.Keywords
This publication has 20 references indexed in Scilit:
- Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 casesBlood, 2005
- Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndromeBritish Journal of Haematology, 2005
- Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune DiseasesAnnual Review of Medicine, 2004
- Recent Advances in Thrombotic Thrombocytopenic PurpuraHematology-American Society Hematology Education Program, 2004
- Thrombotic MicroangiopathiesNew England Journal of Medicine, 2002
- Mycophenolate mofetil, Cellcept®, a new immunosuppressive drug with great potential in internal medicineThe Netherlands Journal of Medicine, 2000
- Preliminary Risk-Benefit Assessment of Mycophenolate Mofetil in Transplant RejectionDrug Safety, 1997
- Ineffectiveness of high‐dose intravenous gammaglobulin infusion in thrombotic thrombocytopenic purpuraAmerican Journal of Hematology, 1993
- Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpuraThe Lancet, 1990
- Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresisAmerican Journal of Hematology, 1990